Weekly adaptive radiation for prostate cancer spread to lymph nodes
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a high-precision, short-course radiation treatment for prostate cancer that has spread to a few lymph nodes in the pelvis. The treatment uses weekly MRI or CT scans to adapt the radiation to your exact anatomy, aiming to target the cancer while protecting healthy tissue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- Your prostate cancer has spread to 5 or fewer lymph nodes in the pelvic area, but not to other parts of the body.
- You need to have had both a PSMA PET scan and an MRI to confirm the staging.
- You should be in fairly good health – able to carry out daily activities.
- You must not have had radiation to the pelvic area or prostate before, and you haven't had your prostate removed.
- You should not have severe urinary symptoms or other major health conditions that might interfere with the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a newer, more precise radiation treatment that gives a higher dose to the main tumor while keeping radiation to the rest of the prostate the same. It is for men with intermediate- or high-risk prostate cancer who haven't had prior prostate radiation or removal.
This trial compares two ways of giving radiation to the prostate and pelvic lymph nodes. It also tests two different instructions for how full your bladder should be during treatment. The goal is to see which approach works better and is easier for patients.
This trial tests a radiation plan that is adjusted every day using your own scans to better target prostate cancer. It may help reduce side effects while still treating the cancer effectively in men with lower- or intermediate-risk disease.
This trial tests a precise type of radiation therapy (called SABR) for prostate cancer that has returned in the lymph nodes only. It aims to control the cancer with fewer side effects and might offer a treatment option when surgery or other standard treatments are no longer enough.
This trial tests whether giving higher radiation doses to the prostate and pelvic lymph nodes is more effective than treating only the prostate. You may benefit if your prostate cancer has spread to nearby lymph nodes but not to bones or other organs, and you are getting hormone therapy.
This trial tests a type of focused radiation therapy for men with intermediate or high-risk prostate cancer that hasn't spread. It aims to improve outcomes by targeting the main tumor seen on MRI.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.